VANCOUVER, BC--(Marketwired - September 22, 2016) - Sirona Biochem Corp. (TSX VENTURE: SBM)
(FRANKFURT: ZSB) (XETRA: ZSB) (the "Company")
announces that all resolutions tabled at its Annual General Meeting held on September 21, 2016, were passed. The resolutions
included:
- Fixing the number of directors of the Company at seven;
- Electing Geraldine Deliencourt-Godefroy, Christopher Hopton, Alex Marazzi, David Moore, Martin Gleave, Casper Bych and
Howard Verrico as directors;
- Appointing MNP LLP, Chartered Accountants, as the Company's auditor for the ensuing year and authorizing the directors to
set the auditor's remuneration;
- Confirming and approving the Company's existing stock option plan
The Company also announces that is has granted incentive stock options under its stock option plan to employees and
consultants for the purchase of 1,600,000 common shares of the Company at a price of $0.20 per share.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum
revenue potential.
Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific
awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts
may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve
known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results,
performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking
statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements
about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory
approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its
products that could delay or prevent product development or commercialization; the scope and validity of patent protection for
its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to
support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required
by law.